Sponsored by

VGoodiez 420EDC
  • Welcome to VaporAsylum! Please take a moment to read our RULES and introduce yourself here.
  • Need help navigating the forum? Find out how to use our features here.
  • Did you know we have lots of smilies for you to use?

Law The Cannabis Chronicles - Misc Cannabis News

Fairly confident that we can get legalization without him.

Indeed this is true, but I do believe he deserves some respect. He was advocating for cannabis from a time before there even was big MJ, IMO.

Now Whitaker, well...I'm not that interested in him. He's acting only and will never be confirmed as AG....can't even see him being nominated but I have most def been wrong before.

How will Matthew Whitaker approach cannabis as new Attorney General?

On Wednesday, Jeff Sessions, former Alabama Senator and indefatigable opponent of legal cannabis, lost his job as Attorney General of the United States. Trump, who appointed Sessions to AG upon taking office, soured toward Sessions after he recused himself from the Mueller investigation. Since that recusal, Trump has repeatedly blasted Sessions, publicly expressing his discontent with his AG. And with the hurdle of the midterm elections behind him, Trump finally asked Sessions to resign. Trump’s choice for a replacement AG, Matthew Whitaker, was a choice out of left–or in this case, right– field, and it caught many off guard. How will the new attorney general impact the cannabis industry?

Matthew Whitaker is No Jeff Sessions, but How Will He Approach Cannabis as Attorney General?
Trump appointed Matthew Whitaker as acting attorney general immediately after forcing out Jeff Sessions. Whitaker was Sessions’ chief of staff. But it appears he made it onto Trump’s radar over his vociferous opposition to the investigation into the Trump campaign’s possible collusion with Russia to influence the 2016 election. But while Whitaker’s stance on Mueller dominates the headlines, the cannabis industry is right to wonder how Whitaker differs from Sessions in terms of his views on state-legal cannabis.

However, we know very little about how Whitaker would approach cannabis as attorney general. In 2014, during a primary debate for the Republican U.S. Senate nomination from Iowa, Whitaker expressed support for Iowa’s then-recent legalization of cannabidiol (CBD). But during the same debate, Whitaker also expressed disagreement over the hands-off approach Obama’s attorney general, Eric Holder, had taken with respect to state laws legalizing cannabis. It’s important to place those remarks in the context of a heated primary contest. Whitaker may have offered his criticisms of the Obama-era Cole Memo just to score points against his Democratic rivals. Sessions, of course, rescinded the Cole Memo as he stepped into the role of AG, vowing to prioritize enforcement of the federal prohibition on cannabis.

At the very least, Whitaker has no record of doing what Sessions has done. Whitaker isn’t insulting and belittling medical cannabis consumers, ignoring credible and significant research on cannabis. He isn’t vowing to reinvigorate the War on Drugs. And he isn’t on the record saying he thought the Ku Klux Klan “was okay until I found out they smoked pot,” as Sessions said in 1986.

Sessions Ouster is a Good Thing for Cannabis, and Whitaker Likely Won’t Have Much of an Impact
The U.S. Attorney General undoubtedly has a huge role in shaping the domestic cannabis industry. And it would be hard to imagine anyone filling that role who could be more anti-cannabis than Jeff Sessions. Indeed, just hours after Sessions resigned, cannabis industry stock prices surged. Still, an AG hostile to states’ right to legalize cannabis on their own would absolutely depress the industry. Concerns about federal enforcement actions have stymied the industry in numerous ways. And with Sessions now out of the picture, the industry can breathe a bit easier.

Ultimately, though, Whitaker’s appointment is temporary, and in light of recent revelations, also likely illegal for at least three reasons. So Trump’s likely illegal appointment of Whitaker to AG probably won’t hurt the cannabis industry. But it isn’t going to help it either. Until the U.S. government has an attorney general who accepts the science behind medical cannabis, heeds the increasingly bi-partisan consensus on legalization, and makes drug policy reform a priority, the cannabis industry will have to keep a wary eye on whoever is serving as the nation’s top law enforcement official.
 


The complicated relationship between IP law & cannabis


The relatively new industry revolving around the legal growth, distribution, and commercial sale of cannabis represents a golden (or, should I say, green) opportunity for emerging entrepreneurs.

According to leading cannabis researchers, the next decade will see spending on legal cannabis worldwide escalate to $57 billion by 2027. Within this figure, the recreational market will constitute 67% of the spending while the medical market will fill in the remaining 33%. The majority of the industry will take place, on both the buying and selling side, in North America.

For the innovators capitalizing on this green movement, the procurement of intellectual property rights can go a long way in the monetization of their cannabis-related ideas, products, and services. As with any new venture, solidifying an IP protection strategy early on can maximize the benefits of a new invention and minimize risk the of potential infringement. This rings especially true in a field where so few patents, copyrights, and trademarks have been issued.

Only a yellow light for green entrepreneurs on the road to IP protection
As one can imagine, given the complicated and controversial history of marijuana legalization, there are many obstacles and complexities that green entrepreneurs face in securing IP rights on their pot products.

This article will specifically focus on the problems and solutions in trademarking, patenting, and licensing cannabis-related inventions.

Conflicting federal and state regulations
The biggest roadblock in securing general IP rights in the cannabis market comes from the fact that marijuana remains illegal under federal law, while many of the more progressive states have wholeheartedly embraced medical and/or recreational marijuana use through legalization.

Cannabis continues to be a Schedule I drug under the Controlled Substances Act, which means that federal law prohibits possession of cannabis. However, 29 U.S. states and the District of Columbia have legalized medical cannabis, while eight U.S. states have legalized recreational cannabis.

Troubles with trademarking
For green innovators seeking IP protection via securing a trademark, these conflicting laws may cause some complications due to lawful use rules. To protect a brand by registering a trademark with the U.S. Patent and Trademark Office, the trademark must be used in a commercial way consistent with applicable laws.

Therefore, before federal registration can issue for a trademark, lawful use and legal applicability must be declared and proven.

Under cannabis, there is a great potential for friction with these lawful use rules. The potential violations that arise here center around the Controlled Substances Act (CSA) and the Food, Drug and Cosmetic Act (FDCA).

Loopholes to lawful use rules
Many inventors have seen a loophole in that goods and services related to cannabis are more likely to be granted patents than inventions for primary marijuana products or services. For example, a website, such as a dispensary search service like Weedmaps or a marijuana delivery service like Eaze, will be easier to to protect as intellectual property as opposed to a specific marijuana strain or growth method.

Another loophole is that while it may be more difficult for a cannabis entrepreneur to obtain a federal patent, there are several states that afford trademark protection to cannabis-related goods and services. These states — including Washington, Oregon, Nevada and Colorado — allow for the registration of cannabis-related trademarks. Cannabis entrepreneurs can therefore turn to these states to carry out their intellectual property considerations rather than combat lawful use rules in obtaining a federal trademark.

Finally, green entrepreneurs can protect their goods or services through common law. This protection happens as soon as the entrepreneur uses their product in commerce with a specific and distinctive mark. There are no lawful use requirements to protect a mark under common law, so this method can eliminate roadblocks for those seeking to innovate in the cannabis space.

Pot and patent protection
There are currently around 60 active patents for cannabis, on everything from methods of hydrogenating cannabis oil, to names of specific cannabis plant strains, to a cannabis-infused milk product. The fact that certain strains are patented demonstrates that it can be done.

Marijuana growers can apply for plant patent applications. These are available for inventors who have found a new species of plant which can be duplicated through asexual reproduction. As with any patent, the inventor bears the burden of proving that their cannabis plant is not a naturally occurring substance as is; rather, they have altered a natural substance so that the invention is new and novel.

Another complication in patenting a plant revolves around the fact that cannabis is a plant that is sexually reproduced, and plants that grow this way are ineligible for patenting. Therefore, the cannabis grower has to prove that their plant can grow without both the male and female plant.

J.D. Houvener, founder & CEO of Bold IP, explains that “an individual has to prove that their plant specimen can be asexually reproduced in a lab setting to get patented. If the seed of the plant is genetically modified in a lab setting, then that plant can be patented. If, however, the seed needs another seed, it cannot be protected under the patent law. This is something that is very difficult to prove.”

The types of cannabis-related patents
To qualify for patentability, the USPTO stipulates that the claimed invention must be new, useful and nonobvious. Cannabis patents and applications are subject to this same standard. Types of that may be patentable under this rule are:

  • Cannabis plants, such as new strains of cannabis plants, GMO cannabis, cannabis cultivation methods and equipment, etc.
  • Cannabis processing and extraction methods
  • Cannabis products, such as cannabis in edible or beverage form, cannabis oils and extracts, and products for animals
  • Medical uses for cannabis, such as treatments for a disease or a disorder
Licensing the cannabis leaf
If a grower can demonstrate that their cannabis plant breed is new and novel, they can obtain a licensing agreement that grants them plant breeders’ rights (PBR). PBR’s are a form of intellectual property rights by which breeders can protect their new varieties.

These rights, granted to the breeder of a new variety of plant, can give that breeder exclusive control over the plant material, including over the seed, cuttings, divisions, tissue culture, harvested material, etc.

In Conclusion
It is not impossible to secure IP rights on cannabis-related inventions, but there are a number of factors to consider and a number of complexities to be aware of. If you are a cannabis grower seeking to learn more about filing a plant patent application, you can find a patent guide available here.
 
"Unlike my predecessor, I'm not going to block amendments for marijuana,"
Yep, we got more than one Sessions out of the path for MJ reform.


New Head Of The House Rules Committee Says Federal Cannabis Laws Are 'Way Behind' Public Opinion


As Representative Jim McGovern (D-MA) takes over as chair, the House Rules Committee may no longer be the place cannabis reform goes to die.

"Unlike my predecessor, I'm not going to block amendments for marijuana," McGovern told The Boston Globe. He was of course speaking of the former Rules Committee chair Representative Pete Sessions (R-TX), who lost his seat in Congress in this week's midterm elections. Sessions was well-known for his rigid, anti-marijuana stance, blocking most of the bills that came his way, something McGovern said was out of step with voters' opinions.

"Citizens are passing ballot initiatives, legislatures are passing laws, and we need to respect that. Federal laws and statutes are way behind."

McGovern says he understands full cannabis reform on a federal level would be challenging, but he is committing himself providing protections from federal interference for individual states that do decide to legalize the substance. Additionally, he plans to focus on opening up banking services to cannabis businesses, a problem that has long held back smaller companies that don't have access to wealthy investors from getting off the ground. And to tie things off, McGovern says he hopes to push Veterans Affairs to provide medical marijuana to vets in states where the substance is otherwise legal.

"This just seems like common-sense stuff," McGovern said. "Especially on the issue of medical marijuana—people who are opposed to that are just on the wrong side of public opinion, overwhelmingly. It'd be nice if, every once in a while, Congress acted in a way that people wanted. I know that may seem like a radical idea, but come on."

It has yet to be seen where McGovern's effort will lead given the unpredictable nature of the Trump administration. However, one thing is clear: Now that both of the anti-marijuana Sessions are out of the way, feds may actually rise to the call of cannabis policy reform.
 
I expect Whittaker to be in favor of handing cannabis to the Big Money, ‘cause there’s big money in cannabis, and Big Money wants it. ALL of it.

I also have real issues with the “states’ rights” argument, especially since prohibition was entirely a Federal imposition. ALL state laws governing cannabis came after that, because forfeiture, because Federal favor, because school-to-prison pipeline.

I’ve been using the example of corn: anyone who wants to grow corn can, anyone who wants to eat corn can, anyone who wants to make things out of corn can. THAT is legalization. Whoever and whatever, cannabis rightfully should be cleared for unrestricted use, and all state laws mandating penalties for cannabis should be nullified explicitly by the shift in the Federal stance.
 
How losing pro-marijuana Republicans in congress could affect legalization

Last Tuesday, Democrats retook control of the House of Representatives, a development that many marijuana advocates celebrated, writes Joseph Misulonas. But now some are wondering if losing pro-cannabis Republicans may actually hurt the cause.

Several pro-marijuana Republicans lost their bids for re-election last week during the midterm elections. This included Dana Rohrabacher, arguably the biggest champion for cannabis laws in Congress the past few years, Carlos Cubelo, who's attempted to push laws to make banking and taxes easier for marijuana businesses, and Mike Coffman, who pushed to protect states that legalized marijuana like his home state Colorado.

There are a few reasons this could hurt legalization. Without pro-marijuana voices from Republicans in Congress, Democrats will basically write all cannabis bills themselves, and will probably not include amendments or changes that would appeal to conservatives. So while Democrats in the House may like it, there's no way Republicans in the Senate would approve them.

Another issue is that it may prevent other Republicans from adopting pro-cannabis views. They saw that supporting cannabis didn't help attract moderate voters in last week's election, so they'll assume it won't help them either, giving them less incentive to support the issue.

But these members losing also ensured that Democrats would take control of the House, and therefore remove Republican leadership who were stonewalling legalization every step of the way.

We'll see over the next few years if these midterms were the boost marijuana legalization needed, or if there's still more work to come.
 
Two related articles, first is an intro to the series and the next is Part I.


Cannabis Goes To Washington
A burgeoning industry is using its money to influence politics, and finding new GOP allies in the process. But there may be a price.

In August of 2017, a mysterious political action committee formed called the Federalist Freedom Fund. It was a joint fundraising committee between two Republican congressmen, Carlos Curbelo and Mike Coffman, as well as the two major Republican election committees, the National Republican Congressional Committee and the National Republican Senate Committee. Within a month, it raised $187,700. Six months later, it shut down and the money was disbursed four ways.

On its surface, the Fund was a standard PAC meant to support Republican causes, although it had no website or mission statement. Only after looking at the PAC’s donors would its purpose become clearer: Every single one of its donors was a giant in the booming multibillion-dollar cannabis industry. Coffman and Curbelo, who both lost reelection bids in the midterm elections last Tuesday, not only represent the key adult-use and medical cannabis markets of Colorado and Florida, respectively, but they have been rare and vocal cannabis backers in a GOP-dominated Congress.

Today, two in three Americans support legalization, according to an October Gallup survey, the type of overwhelming voter support that has begun to push even the most resistant politicians to embrace the issue.

SUBSCRIBE TO CANNABIS WIRE'S MORNING NEWSLETTER
Original news and analysis from veteran journalists—straight to your inbox every weekday morning. (This newsletter is free now, but will soon be available only to subscribers.)

Email Address

The formation of the Federalist Freedom Fund marked a significant turning point. The cannabis movement has given birth to a cannabis industry, and that industry, like any other, wants to promote its own interests. And now the industry has matured enough to afford to set and pursue its own priorities. It’s not uncommon for CEOs to support candidates who support them, so the fact that cannabis businesses donated to Coffman and Curbelo should come as no surprise. But because of how the money was split, the Fund’s donors also supported all Senate and Congressional Republicans—an example of how the new cannabis industry has begun to wade more aggressively into the political sphere, and to court Republican lawmakers. The party’s support for states’ rights and free markets overlaps with the goals of an increasingly wealthy industry that is focused on taking care of business. Priorities are shifting. What gets lost and gained in the process?

Meanwhile the days of grassroots and philanthropist-backed efforts—spearheaded for decades by the movement’s pioneer cannabis advocacy groups like the National Organization for the Reform of Marijuana Laws (NORML), formed in 1970, and the Marijuana Policy Project (MPP) formed in 1995—could be waning. And, looking to cannabis law reform in the coming years, these groups could see their influence diminished in Congress, as the emerging industry opens its checkbook for lobbyists and lawmakers, potentially pulling focus toward business interests and away from, for example, criminal justice-related priorities.

When it comes to federal lobbying and direct donations to candidates and their PACs, the largest and oldest cannabis organizations in the country have already been dramatically outspent this year: Just under $1 million was spent by cannabis organizations, and just under $2 million by cannabis companies and their executives. Across the board, that spending is on the rise.

lobbying-11.png

Image credit: Ben Jay
This is not a lot of money when compared with what other industries spend in Washington, DC. But it’s indicative of a foundational shift toward business-friendly legislation and priorities, a sea change that goes deeper than the flip of the House to Democrats in the midterm election.

In this series, we will explore these changing dynamics to ask what these new players and priorities mean for the future of cannabis in America.

PART I: Cannabis Courts the Grand Old Party
The cannabis debate in Congress is being reshaped along GOP-friendly lines.

Many Republicans in Congress often assert two core beliefs: states’ rights and free markets. And though the Democrats managed to turn the House blue in the midterms, the only way cannabis legislation will move through a GOP Senate and White House in the near future is on a bipartisan basis. That reality comes as the cannabis debate in Congress is beginning to be reshaped along GOP-friendly lines.

Because cannabis is no longer in the domain of an anti-corporate counterculture, it is becoming a more natural sell. Already, pharmaceutical, tobacco, alcohol, and beverage industries—all hefty spenders in Washington—have begun to formulate plans for cannabis-based products, from Coca-Cola’s trial balloon interest in CBD beverages to the record $4 billion investment by Constellation Brands, the parent company of Corona beer, in one of the largest Canadian cannabis companies.

Where the industry forms alliances in Congress will shape its future, partly because it is so young. Despite the industry’s multibillion dollar growth and potential, these are early years: The first legal adult-use sales in the US began in 2014.

During the past two years, the cannabis industry has sought to push not just cannabis legalization, but a business-friendly list of goals in Congress, including tax reform. Increasingly, members of the GOP—previously staunchly anti-cannabis, with few exceptions—are supporting those legislative efforts. Even if lawmakers are simply responding to a new political landscape as more states legalize, the pace at which the GOP has begun to display a more receptive attitude on cannabis has been swift.

Cannabis Wire’s review of government data found a ten-fold increase over the last seven years in the number of GOP House and Senate members who have sponsored or cosponsored bills and resolutions related to cannabis: from twenty-three co-sponsors in 2011 and 2012, to 256 from 2017 to the present—the most in any Congress.

Democrats, meanwhile, have hardly been sitting on the sidelines. They have also dramatically increased their participation as co-sponsors during the same period, from 117 to 652, or nearly five-fold.

gop-bills.png

Image credit: Ben Jay
On the Republican side, to be sure, the cannabis romance remains somewhat tentative. Former Attorney General Jeff Sessions, the nation’s top law enforcer until President Trump forced him out right after the midterm election, has been obstinate when it comes to cannabis. In January, Sessions, a Republican from Alabama, ruffled Democrats and Republicans alike with his anti-cannabis rhetoric and repeal of Obama-era protections against federal meddling in state-legal cannabis activity.

Party leaders have distanced themselves from the national public discussion over legalization, and one Republican in particular became a legislative roadblock: From his perch as chairman of the House Rules Committee, Texas Republican Congressman Pete Sessions frustrated many in the cannabis law reform community by blocking some cannabis-related measures from advancing. The Texas Cannabis Industry Association targeted Sessions for his anti-cannabis views, perhaps contributing to his loss Tuesday to Democrat Colin Allred, who supports medical cannabis. Oregon Representative Earl Blumenauer, co-chair of the Congressional Cannabis Caucus, formed in 2017, recently told Cannabis Wire, “Pete Sessions is enemy number one.” House Speaker Paul Ryan, meanwhile, has said and done little on the issue.

Yet these factors effectively hid the churn of action below the surface.

SUBSCRIBE TO CANNABIS WIRE'S MORNING NEWSLETTER
Original news and analysis from veteran journalists—straight to your inbox every weekday morning. (This newsletter is free now, but will soon be available only to subscribers.)

Email Address

Over the past two years, Cannabis Wire found, major cannabis industry players spent $218,100 on GOP-aligned candidates and PACs and $95,000 on Democratic-aligned candidates and PACs, according to the most recent FEC filings.

Some of these players:

• Brendan Kennedy, a founder of Privateer Holdings, donated $20,000 to groups and candidates aligned with the GOP and $9,400 to Democrats.

• LivWell CEO John Lord donated $36,300 to GOP candidates and affiliated PACs, and $11,000 to campaigns and PACs affiliated with Democrats during that time period.

• In just the last two years, MedMen CEO Adam Bierman donated $28,600 to Democrats and affiliated PACs and $14,100 to members of the GOP and Republican-affiliated PACs.

Don Murphy, a lobbyist for the Marijuana Policy Project (MPP) and a former GOP member of the Maryland legislature, said of the cannabis industry, “If you want to be a player you’ve got to play,” adding, “You need to be supportive of the people who support you. If you don’t help these guys they could end up losing, and those who were against our position will say, ‘Look what it got them.’”

This year, MPP, which works primarily at the state level as one of the oldest cannabis advocacy groups in the country and is responsible for the passage of many medical and adult-use cannabis laws in place today, spent $26,000 on federal candidates and PACs (of $110,242 raised for those purposes). Of that total, $12,000 went directly to Republican campaign committees. And just under half of that $12,000 went to Representative Dana Rohrabacher, a California Republican and longtime supporter of cannabis legalization. Rohrbacher lost his reelection bid last Tuesday. While cannabis legalization is typically linked to more liberal politics, Rohrabacher has a particularly #MAGA perspective: He opposes immigration reform and supports Russian President Vladimir Putin.

Murphy told Cannabis Wire that the group supports its allies, period. “It wasn’t long ago that Democrats controlled everything and we got nothing,” he said, referring to the first two years under the Obama presidency.

Rohrabacher was not the only unexpected GOP advocate in Congress using cannabis money to help support a campaign. For example, Surterra, a medical cannabis company with businesses in Florida and Texas, contributed to Florida Republican Representative Matt Gaetz’s successful re-election bid, donating $15,000 to a Gaetz-affiliated Super PAC, North Florida Neighbors, according to the latest campaign filings; the company’s CEO also gave $10,800 to Gaetz’s campaign committee. Gaetz has become one of the most outspoken cannabis advocates in Congress and in his home state, where voters cast ballots to legalize medical cannabis in 2016. He has also been in the news lately for another reason: perpetuating the myth that billionaire George Soros paid migrants to flood the US.

Representative Tom Garrett, a Republican from Virginia who is leaving Congress, told Cannabis Wire that industry dollars would begin to influence members of Congress. Money in Congress, he said, matters.

“I’m not saying that everybody here alters their vote based on who supports them monetarily,” he said. “I’m just saying that a lot of people do.”

Republicans have become more outspoken about legislation that is most important to the cannabis industry. Senator Cory Gardner, Republican from the purple state of Colorado, went head-to-head with Trump by blocking his Department of Justice nominations until Trump promised in April not to interfere in state-legal cannabis. Gardner then teamed up with Democratic Senator Elizabeth Warren to push the Strengthening the Tenth Amendment Through Entrusting States Act, commonly called the STATES Act. The measure would protect state-legal cannabis activity from federal interference, and would address many industry concerns that result from federal prohibition, such as access to banking. (The measure falls short of national legalization, which means many criminal justice questions would remain unanswered.)

And Senate Majority Leader Mitch McConnell has become Congress’ most outspoken advocate for hemp, and is pushing for full hemp legalization under the 2018 Farm Bill. (While McConnell is not in support of marijuana law reform, hemp is linked to the broader cannabis issue since its legality falls into a gray area under the Controlled Substances Act and since there is some industry overlap when it comes to CBD products.)

Already, some cannabis industry members have specifically targeted the GOP to work on a core business priority: tax reform. Patrick Raffaniello is a longtime lobbyist mostly on tax issues, including work for PricewaterhouseCoopers and the National Rifle Association. He was contracted by a new cannabis industry political fundraising group called the New Federalism Fund (NFF), a non-profit formed in 2017 and funded primarily by executives of three of the industry’s leading companies: LivWell, Scotts Miracle-Gro, and Privateer Holdings, according to federal lobbying disclosures.

It had a very specific goal. “NFF, at the beginning of last year, formed itself to try to talk to Republican members of Congress in a language they would understand,” Raffaniello told Cannabis Wire. “What NFF did is they said, ‘OK, let’s talk about this in terms of states rights.’”

NFF chose to focus on something that crushes many cannabis business owners—the inability to write off traditional business expenses on their federal taxes, prohibited by the now-infamous (in cannabis circles) tax code section 280E. In two years, the group spent around $1.4 million on lobbying related to cannabis, taxes and related issues, according to federal disclosures filed with the US Senate. (Some of those disclosures show up under the now-affiliated group Cannabis Trade Federation.)

Congress, though, wasn’t ready. Yet while that push on taxes wasn’t successful, Raffaniello believes he saw an industry beginning to grapple with how to meet its goals in Washington.

Raffaniello told Cannabis Wire that members of Congress involved with taxation issues were initially taken aback at his ask on behalf of the cannabis industry in 2017. “Very few of them had any background on cannabis and a lot of them thought it was funny to have a tax guy come in and start talking about marijuana,” Raffaniello said.

The GOP faces the task of striking a balance between a long record of moral opposition to cannabis and a strong belief in the Tenth Amendment, which conservatives argue should limit the federal government’s powers. “It’s a tough call for members, but they also recognize that it would be hypocritical to say ‘we want states’ rights — except when we don’t,’” Raffaniello said.

In announcing the STATES Act, Republican Cory Gardner of Colorado focused on the need to limit the federal government’s power over his state’s cannabis industry, while Warren spoke about the war on drugs and how law enforcement has used cannabis to aggressively police communities of color.

The STATES Act “ensures the federal government will respect the will of the voters—whether that is legalization or prohibition—and not interfere in any states’ legal marijuana industry,” Gardner said in his statement.

It’s a simple, uncluttered argument that allows a GOP lawmaker to be not so much on the side of cannabis, but to be on the side of voters and states’ rights. A cannabis industry spokesperson couldn’t have said it better.
 
So, I go into dispensaries and if I make a comment that THC % isn't everything, the bud tender will inevitably say "yeah, its the terps". Now, to me the first statement is absolutely true as i have gotten some very high THC strains that just didn't trip my trigger (just kind of missing the guts of the effect...not sure how else to describe it...maybe thin) while I have had some in the mid-teens on % but were very pleasant and nice.

My issue is with the rejoinder from the bud tenders...yeah, its the terps...and yeah, I know you look at the label to see terp %....but no, you have absolutely NO idea of how and in what combinations these terps and minor cannabinoids come together to drive a specific effect profile. This is the issue facing all of us. Ok, its one thing to say Myrcene is sedative...but its another to look at a complex mix of teprs and minor cannabinoids and predict its effect.

That's why I think this is a VERY important initiative.


The Feds Want Researchers To Study ‘Minor’ Cannabinoids And Terpenes In Marijuana

Tetrahydrocannabinol (THC)—the marijuana compound known for getting you high—is the most well-know cannabis constituent. In recent years, cannabidiol (CBD) has garnered attention for its non-intoxicating medicinal properties.

Now, the federal government is recruiting researchers to investigate how the dozens of other lesser-known cannabinoids and terpenes work and whether they can treat pain.

It’s going to be a weighty task for any interested parties. There are more than 110 known cannabinoids and 120 terpenes, very few of which have been extensively studied. The federal research project will cover all “minor cannabinoids,” which is defined as anything other than THC, according to a pair of funding notices published by the National Center for Complementary and Integrative Health this week.

“The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to pain relief and functional restoration in patients with different pain conditions may be very broad,” the notices state. “This initiative encourages interdisciplinary collaborations by experts from multiple fields—pharmacologists, chemists, physicists, physiologists, neuroscientists, psychologists, endocrinologists, immunologists, geneticists, behavioral scientists, clinicians, and others in relevant fields of inquiry.”

Numerous studies have established that ingredients in marijuana such as THC and CBD effectively treat various types of pain. There’s also some evidence that other cannabinoids and terpenes contribute to the therapeutic efficacy of cannabis, working synergistically to bolster the plant’s overall benefits—a phenomenon called the “entourage effect.”

But there’s still a lot of work to be done to fully understand the mechanisms through which each cannabinoid and terpene influences pain. If researchers can pinpoint which ingredients are best suited for pain relief, it could inform new therapies. For example, there’s evidence that certain cannabinoids can enhance the pain-relieving effects of opioids, the notice states, so discovering exactly which ones achieve that end can hypothetically help patients take lower doses of addictive painkillers.

“The development or identification of novel pain management strategies is a high priority and unmet need. Natural products have historically been a source of novel analgesic compounds developed into pharmaceuticals (e.g., willow bark to aspirin). A growing body of literature suggests that the cannabis plant may have analgesic properties; however, research into cannabis’s potential analgesic properties has been slow.”

In addition to CBD, the feds say they are particularly interested in research on the following compounds: cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), myrcene, ß-caryophyllene, limonene, a-terpineol, linalool, a-phellandrene, a-pinene, ß-pinene, terpinene and a-humulene.

The estimated deadline to submit an application for research funding is March 8, 2019
 

Top Lawmakers In Two States Optimistic About Marijuana Legalization In 2019

Voters in several states elected new governors who support marijuana legalization last week. Now, top legislative leaders in two of those states—Illinois and New Mexico—say they are optimistic about the chances of getting bills to end cannabis prohibition to the desks of those new state chief executives after they take office next year.

“[M]y guess is if it were to make it to the floor, it would probably pass the House,” Rep. Brian Egolf (D), the speaker of New Mexico’s House of Representatives told the Santa Fe Reporterin an article published on Tuesday.

Also on Tuesday, the Associated Press reported that Illinois House Speaker Michael Madigan (D) supports Democratic Gov.-elect J.B. Pritzker’s plans to push for marijuana legalization, which he campaigned heavily on.

Madigan had previously been noncommittal on ending cannabis prohibition, saying earlier this year that he hadn’t “come to a final decision” on where he stood on the issue. His backing will be key to getting a legalization bill to Pritzker to sign.

In New Mexico, the prospect of legalization got a huge boost with the election of ‎Michelle Lujan Grisham (D) as the state’s next governor.

But while Egolf, the speaker, is optimistic about House passage, the state’s Senate has historically been less open to cannabis reform. That said, even some lawmakers in that chamber who personally oppose marijuana use now seem ready to back legalization.

“I don’t want recreational marijuana, but I understand the political reality that it is here,” Sen. Mark Moores (R) told the Santa Fe Reporter. “I want to make sure we have a system that is extremely well-regulated, and the ability to take those revenues and mitigate some of those negative social impacts that marijuana has.”

Senate Majority Floor Leader Peter Wirth (D) is also hopeful about getting a legalization bill to Lujan Grisham in 2019, saying that it would “lead to huge economic development.”

Pritzker and Lujan Grisham are two of more than 20 major party gubernatorial nominees who endorsed marijuana legalization ahead of this month’s midterm elections.
 
Hey, @momofthegoons - where did the Jeff Sessions thread go???


10 cannabis executives predict how AG Jeff Sessions' retirement will affect the marijuana industry

When Attorney General Jeff Sessions tendered his resignation on November 7th, the cannabis industry took notice. As one of the most vocal marijuana opponents in the highest level of U.S. government, his resignation could pave the way for federal legalization.

With Matthew Whitaker set to take Sessions’ place, the industry could be poised for significant change in the near future. How do cannabis industry insiders feel about this news? Will it be as groundbreaking as many hope? Here are insights and predictions from 10 cannabis and hemp industry executives to provide some perspective.

Derek Peterson, CEO of Terra Tech
“Attorney General Jeff Sessions has been an impediment to the growth of the regulated cannabis industry. We believe we are at a tipping point nationally in terms of voter sentiment as well as support from lawmakers on both sides of the aisle. With Pete Sessions being voted out [of Congress] and Jeff Sessions resigning, the corridor is now open to accelerate a states’ rights approach to regulating the cannabis industry.”

Isaac Dietrich, CEO of MassRoots
“We believe it’s increasingly likely Congress could take action to regulate and tax cannabis at the federal level. We expect the perceived risks related to the cannabis industry to continue to dissipate, which could lead to a shift of institutional capital and interest from Canadian licensed producers to companies focused on the regulated United States market.”

Charlie Finnie, Chief Strategy Officer of MariMed Inc.
“Although we wish Mr. Sessions well, he was woefully out of step with the American people with regard to the myriad health and wellness benefits of cannabis. When the Republican ex-speaker of the House John Boehner writes an Op-Ed piece entitled 'Cannabis Should be Legalized,' that tells you all you need to know.”

Khurram Malik, CEO of Biome

“AG Sessions’ anti-cannabis rhetoric was a lot stronger than any other part of the federal government, including Congress and the White House, and quite a few things he announced were inconsistent with other parts of the government. Ultimately, most of his anti-cannabis rhetoric and attempted policies did not have a granular impact.

“The hope is that there will be a lot less confusion and distracting noise coming out of the AG’s office on a go forward basis. We also still expect the White House to move forward with legalizing medical cannabis at the federal level before the 2020 elections, and having an AG that is on board with that would be helpful for all.”

Dr. Stuart Titus, CEO of Medical Marijuana Inc.
“The unexpected resignation of U.S. Attorney General Jeff Sessions represents another positive event for the cannabis industry. Sessions' stance on cannabis had been a major impediment toward cannabis reform, and now industry participants hold new hopes for sweeping change at the Federal level. Along with the defeat of Pete Sessions in the U.S. House of Representatives, there is renewed enthusiasm for cannabis-friendly legislation to be passed in the coming year.”

Jeffrey M. Zucker, President of Green Lion Partners
“Jeff Sessions and his ignorance leaving office is a definite win for cannabis patients, the movement and the fight to end the drug war and its racially disparate enforcement as a whole. We’ll have to wait and see how Matthew Whitaker approaches cannabis, but it can’t get much worse than Sessions, and hopefully, this is the start of some federal progress and protection for those participating in cannabis in the many states that have enacted laws. President Trump has seemed amenable to making cannabis a states’ rights issue, and it wouldn’t surprise me if we see changes to that effect on the federal level in the near future.”

George Archos, CEO of Verano Holdings
“The election results send a clear message that more Americans want access to medical or adult-use cannabis because they have taken the time to get educated about cannabis’ proven health benefits. Former AG Sessions and other government officials lose credibility by maintaining that cannabis has no medicinal value when our own FDA has approved a cannabis-derived drug for treating epilepsy.”

“President Trump has repeatedly stated he will protect states’ rights relative to cannabis, and more recently, he stated he is exploring ending the prohibition on cannabis. We are optimistic that a new Attorney General will take President Trump’s cue and quickly reinstate the Cole memo to end ambiguity regarding states’ rights in this matter.”

“Additionally, we hope the new Attorney General will determine that it is not wise to spend tax dollars on incarcerating thousands of people for marijuana convictions when cannabis has been proven to be safer than the alcohol found in almost every American household.”

Wil Ralston, President of SinglePoint
“Jeff Sessions' resignation could be a huge event for the cannabis industry since he has openly been against the industry and used his powers to slow its growth. One of the biggest potentials here is opening up access to banking.”

Frank Lane, President of CFN Media
“The resignation of Jeff Sessions marks another key turning point for the cannabis industry, removing a key obstructionist to cannabis reform from the Justice Department. Many cannabis stocks have already surged following the news in hopes that the resignation will usher in a change to federal cannabis policy, including passage of the STATES Act. We are cautiously optimistic.”

Bruce Perlowin, CEO of Hemp, Inc.
“Sessions has long been a hindrance to the growth of the marijuana and hemp infrastructure in the U.S. and it's a huge win for the industry to see him resign. We are currently in the process of creating jobs for rural farmers throughout the U.S. by creating a chain of local processing centers so farmers can switch to hemp and make a profit, and this latest policy development should lead to real change that can create jobs and spur an agricultural revolution throughout the U.S.”

One thing is clear based on these ten cannabis executives’ perspectives. The resignation of Attorney General Jeff Sessions is expected to be a positive change for the marijuana industry. With more Americans as well as an increasing number of Republicans and Democrats at all lev
 
PART II: The Cannabis Industry Learns to Play Politics
Cannabis companies are increasingly lobbying and handing out campaign contributions on both sides of the aisle.

This is the second piece in Cannabis Wire’s series, Cannabis Goes to Washington. You can read the Introduction here and Part I here.

Mike Correia has been lobbying on behalf of the National Cannabis Industry Association, known as NCIA, for the past half decade. The Association formed in 2010 and is the nation’s largest industry advocacy group, with just under 2,000 dues paying members. But the Association might no longer be the most influential industry voice in Congress.

Correia told Cannabis Wire that it wasn’t long ago when he could count on one hand the number of lobbyists working on cannabis.

“I’ll be honest with you, I can’t keep up with some of the lobbyists that are now showing up from individual companies,” Correia said. And with new faces and interests lobbying for cannabis, he said, it can feel like people working on islands. “They represent their clients and they don’t want to be part of the larger network of some of the advocacy groups, and some of the circles that we’re in.”

Correia noted that the industry is still in its “infancy.” Still, money spent on cannabis lobbying overall shows a sharp upswing: In 2011, NCIA and the Marijuana Policy Project (MPP), and the Colorado-focused Medical Marijuana Industry Group spent $43,000 on lobbying the House and Senate. Over the next few years, the amount spent on lobbying surged: In 2015, NCIA and MPP spent $540,000. In 2016, they spent $780,000. Over the years, those lobbying dollars went toward a wide range of cannabis-related issues, from veterans’ access to research expansion.

SUBSCRIBE TO CANNABIS WIRE'S MORNING NEWSLETTER
Original news and analysis from veteran journalists—straight to your inbox every weekday morning. (This newsletter is free now, but will soon be available only to subscribers.)

Email Address

Then, with the establishment of the New Federalism Fund (NFF) in 2017, came a new approach to cannabis in Congress. The powerhouse lobbying group—it could be considered more of a trio, considering the fund is backed primarily by LivWell, Privateer Holdings, & Scotts Miracle-Gro, according to federal disclosures—pumped an unprecedented amount of money primarily toward a single business concern: a repeal of 280E, the part of the tax code that prohibits cannabis businesses from deducting expenses from federal taxes. In 2017, NFF spent $987,000 on lobbying, dwarfing NCIA’s total by $426,000.

So far this year, MPP and NCIA have spent approximately $835,000 on federal lobbying and $114,500 on direct donations to candidates and their PACs, split almost evenly between Republicans and Democrats. (Total spend: $949,500.)

But they were far outspent by major industry players, who put nearly $2 million toward federal lobbying and campaign contributions this year. A majority of that total, $1,551,119, was spent on lobbying by some of the largest cannabis companies in the country, including Canndescent, Weedmaps, Palliatech Inc. (now known as Curaleaf), Surterra Holdings Inc., Trulieve, and, through NFF, Privateer Holdings, Scotts Miracle-Gro, and LivWell.

And at least $313,100 went to candidates and their PACs this election cycle from companies including LivWell, Privateer Holdings, Scotts Miracle-Gro, MedMen, and Wana Brands. Of that amount, Democrats were given $95,000 and $218,100 went to Republicans.

lobbying-2.png

Image credit: Ben Jay
Neal Levine, a former executive at LivWell who headed the NFF effort, told Cannabis Wire that the timing of NFF’s formation wasn’t a coincidence. As the GOP and House Speaker Paul Ryan promised comprehensive tax reform last year, NFF wanted to quickly push the repeal of 280E and alleviate one of cannabis operators’ top concerns.

The Fund “was formed really as an organization that could speak to the right from the right in the right’s language in regards to our issues,” Levine said, “since, you know, the cannabis industry is essentially the modern day personification of new federalism.”

In June, a new group formed called the Cannabis Trade Federation, for which Levine has been named chief executive; fourteen cannabis companies are board members. It will also have an immediate singular lobbying goal, this time to push the STATES Act. Levine said that he hopes to provide funds for—and fold into the federation—non-profits such as MPP. “The advantage to us,” he said, “is that we get to work collaboratively with everybody, we get to coordinate the right messengers going to the right offices on Capitol Hill. And the advantage to these organizations is we help raise the money that they’re looking for.”

Rob Kampia, MPP founder and former executive director, said lessons learned at the state level also apply to Congress: The industry alone, he said, won’t pass meaningful cannabis reform with a targeted lobbying approach.

Kampia believes the key to building support for lasting change has four elements: a grassroots effort to mobilize voters and activists; “grasstops,” which are influential, visible spokespeople for the cause; direct lobbying; and positive media coverage.

“Businesses aren’t set up to do that,” Kampia said. “There’s something that these businesses always overlook because they’re not in the business of changing laws. They’ve never changed a state law. They have no expertise in this.”

***

What happens when cannabis groups or businesses give to politicians that might help the cannabis industry’s interests but who also support causes that could be viewed as abhorrent to some consumers?

The industry has already had to confront that scenario. In June, Cannabis Wire reported that What A Country! PAC (WACPAC), a committee founded by Florida Republican Representative Carlos Curbelo in 2015 to support immigration reform, was funded primarily by the cannabis industry. Major donors to the PAC included CEOs and executives of some of the biggest cannabis companies, including MedMen, Columbia Care, LivWell, and Palliatech Inc. (now known as Curaleaf).

While Curbelo, who lost his reelection bid last week, took a moderate approach to immigration — he supports DACA, for example—and the purpose of the PAC, according to its Facebook page, is to support “candidates for US congress who are committed to reforming America’s immigration laws,” the PAC donated thousands to politicians with staunchly conservative, and in some cases extreme, immigration views.

After Cannabis Wire revealed the PAC’s donors, Daniel Yi, a spokesperson for one of WACPAC’s top contributors, MedMen, said the company was unaware that the PAC was related to immigration, and that its intention was only to support Curbelo, a cannabis advocate. That explanation didn’t sit well with cannabis proponents. In light of MedMen’s donation to WACPAC, an activist group called the Massachusetts Recreational Consumer Council announced that it was going to boycott a local event sponsored by the company. (MedMen told both Cannabis Wire and the Massachusetts group that it had requested a refund from Curbelo and WACPAC. According to the most recent campaign filings, the donation has not been refunded.)

Yi told Cannabis Wire in June that the WACPAC donation and aftermath was a “learning experience,” adding “We’re not a political entity. We’re a business,” he said. “And we’re in the business of cannabis.”
 
GROWING SUPPORT

While no one is saying players are high on the ice, some say more and more are getting high off it. This is the story of one player, marijuana and how science and society will impact the NHL.



Fairly or not, we have an image of the GMs who sit in the executive boxes at NHL games. They’re Old School, as their average age (53.9 years) would suggest. At the high end, there’s the Islanders’ 75-year-old Lou Lamoriello. Almost to a one, they’re defined by their seniority and by the game they came of age in. We think we know their values: They are, by nature, conservative. The irony that their livelihoods in their professional dotage depend on a game that depends on youth is mostly lost on them. They buy into the orthodoxy of the sport. They’re wholly invested in the culture of it.

So, we think, they will look askance at the legalization of marijuana in Canada.
While the debate around marijuana use in hockey is nuanced, my reporting suggests NHL executives’ attitudes are not: Most have a low tolerance for anyone in the game who is even an occasional marijuana user; despite marijuana’s potential utility for pain management and anxiety treatment, at least a few executives want nothing to do with any player who touches the stuff. “If I knew that one of my players was using [marijuana], hell, yes, I would be concerned,” said one GM.

The position of the Old, Old School was articulated by Don Cherry on Hockey Night in Canada years back around the news that snowboarder Ross Rebagliati had been stripped of his 1998 Olympic gold medal: “You start with marijuana, then you go to cocaine, then you go to heroin.”

Current NHL execs wouldn’t go to that extreme, but still consider it stuff that ruins careers, that will derail a star player who gives in to temptation. Okay, it’s not right out of Reefer Madness, but when you’re talking about contracts that pay north of $50 million in total, you can understand why they get alarmed. If your team is counting on building through the draft, tapping an 18-year-old with any known vice that could negatively impact his play is problematic, and marijuana is still mostly seen as one.

This is a virtual consensus among GMs, but not a consensus across the entire business. If you look at those who report to the GMs — the staffers who sit beside them in the executive box or at the draft table, or those out in the field looking at draft eligibles or working with prospects — you’ll sometimes hear a dissenting opinion.

This is the story of how attitudes about marijuana will inevitably become more progressive over time. This is a story told by a guy who has recently left the playing ranks and taken a job in a NHL team’s front office. He’s encouraged by the fact that marijuana is being legalized in Canada, in part because he uses marijuana on a regular basis, just as he did in his playing days. Let’s call him Bud.



Big-Read-Marijuana-in-Hockey-sticks-1.jpg



Of course, some NHL players have used marijuana and are using it; they do so almost certainly more than the league establishment suspects. The younger staffers know. They played with guys who used drugs. And in fact, some of those sitting beside the GMs in the management box and the war rooms have not only used marijuana but remain regular users of it.

Says Bud, who was in the league for a good long stretch that ended a few seasons ago: “I’d say right now, 60 to 70 per cent of the players in the league smoke marijuana,” he says. “No doubt there are more players now using marijuana regularly than when I first came into the league. And I think there’ll be a greater awareness and understanding and acceptance [of marijuana use].”

Bud’s own use of marijuana was a secret from management when he was a player, but it was common knowledge among his teammates. Call it an open secret. These days, while he’s holding down a job in an NHL front office, while he’s building his resumé for what he hopes is a long career as a team executive, he’s keeping it on the down low from his GM. And from his Assistant GM.
 
Earlier parts are posted above.

From the article:

"Boehner recently spoke in a promotional video for something called the National Institute for Cannabis Investors, touting membership to the Institute as a way for regular people to profit off the “green gold rush” before cannabis goes fully mainstream. The group, co-founder Mike Ward said in the video, had spent millions pulling together the best research, and Boehner reminded aspiring cannabis investors of his Capitol Hill connections.

The former Speaker told viewers to get involved before Congress and regulators act, and everybody else wakes up to the opportunity. “There’s hundreds of billions of dollars sitting on the sidelines,” he said. “The boat hasn’t left the dock yet.”

What hypocrisy.

PART III: A Sea Change for Cannabis Politics
As legislative priorities shift, what is gained? And what is lost?

This is the final piece in Cannabis Wire’s series, Cannabis Goes to Washington. You can read the Introduction here, Part I here, and Part II here.

The growing cannabis industry is learning how to throw its weight around in Washington. Industry players are increasingly lobbying and handing out campaign contributions on both sides of the aisle. And perhaps most notably, the industry is making unprecedented alliances with Republicans.

For the politics of cannabis, all this amounts to a sea change. But what does it mean on Capitol Hill in 2019 and beyond? As legislative priorities shift, what might be gained? What could be lost?

First, some history: The cannabis legalization movement has roots in the National Organization for the Reform of Marijuana Laws (NORML), formed in the 70s when Congress was closer to decriminalizing cannabis than it’s ever come since. NORML built significant support in Jimmy Carter’s White House for ending arrests of cannabis consumers. Within months of his taking office, congressional hearings were held to discuss the possibilities, and at one of them, Carter’s drug czar, Peter Bourne, director of the Office of Drug Abuse Policy, said, “We believe that the mechanism for discouragement should not be more damaging to the individual than the drugs themselves.”

But Ronald Reagan ramped up the drug war when he took office, and any national movement in favor of cannabis was off the table. Along with NORML, the Drug Policy Alliance (DPA) and the Marijuana Policy Project (MPP)—both formed in the 90s—shifted strategies and focused their efforts at the state level. They got results. California legalized medical cannabis first, in 1996, followed by more than two dozen states in the decades since. Then, in 2012, adult-use ballot initiatives passed in Colorado and Washington. Those landmark achievements stunned a watching world, as these organizations continued to push other state ballot initiatives that flouted federal prohibition.

Today, thirty-three states and the District of Columbia have medical cannabis programs and ten states and D.C. allow adult use. (These numbers are inclusive of the midterms: Last week, through ballot initiatives, Michigan voters approved adult-use cannabis, and Utah and Missouri voters passed medical cannabis.)

Over the years, the groups pushing for changing cannabis laws built a steady argument rooted in a focus on patients with a medical need; on putting an end to the criminal justice-related harms of prohibition, from arrests that disproportionately affected people of color to the enrichment of violent cartels; on how cannabis is safer than alcohol; and on the proposition that legal sales could bring in tax dollars to be spent on public health, education, and research.

However, these are not the conversations toward the top of the agenda for the new, booming industry as it deploys lobbyists to Capitol Hill. The cannabis industry is trying to win in Washington the same way everyone else does: by using money to appeal to the power players in order to promote its business interests. Meanwhile, an increasing number of those power players happen to be in the GOP.

As a result of these factors, the legislation attracting the most resources and attention prioritizes exempting businesses, not consumers, from prosecution.

***

A clear example of the new politics of cannabis is what is commonly called the STATES Act, for Strengthening the Tenth Amendment Through Entrusting States. The specific approach of STATES appeals both to the industry and to Republican support for states’ rights: It would essentially limit the Department of Justice’s right to infringe upon the legal industry at the state level.

For the industry, that means the same banking access and tax deductions granted to typical businesses. For GOP members with a philosophy of limiting federal power, it’s a comfortable fit, and thus has a measure of bipartisan support. The Act was introduced in June by Democratic Senator Elizabeth Warren of Massachusetts and Republican Senator Cory Gardner of Colorado.

The STATES Act is supported by many of the Democrats and organizations (like DPA, MPP, and NORML) that have historically thrown their support at federal legislation in favor of cannabis. The Act can arguably be seen as a step toward fuller reform, an interim goal at a time when Congress is not ready for full legalization.

But there may be tradeoffs, as criminal justice language in STATES is noticeably absent. If legislators take a states’ rights approach to cannabis, black and brown communities in states such as Alabama, in which legalization could take decades if it happens at all, will continue to face arrest and incarceration for cannabis-related crimes.

Legislation that addresses criminal justice does exist in Congress. New Jersey Senator Cory Booker, for example, introduced the Marijuana Justice Act of 2017, which would not only legalize cannabis nationally, but also expunge past cannabis convictions and establish a Community Reinvestment Fund for areas hard hit by the drug war, among other things. But the current reality is that only legislation with the muscle of Republicans and industry giants is likely to make it over the finish line.

Ethan Nadelmann, the founder and former executive director of DPA, foreshadowed this priorities shift in a 2015 interview with one of Cannabis Wire’s founders about a private group in Ohio that self-funded a statewide medical cannabis campaign that, had it been successful, would’ve given the group an oligopoly: “Now we’re entering a world where the principal people who see themselves benefiting are not the people who are not going to be arrested; the principal people who see themselves benefiting are basically the people who are going to make money from this.”

The Ohio campaign was the first time cannabis organizations like MPP and DPA had been bypassed by wealthy newcomers. Nadelmann added that he always knew “that we reformers would not be, over the long term, in such a strong position to shape what legalization would look like. Especially in the United States with its dynamic capitalist system.”

Alison Holcomb, the director of Washington’s legalization campaign in 2012 and then criminal justice director at the ACLU of Washington, worried back in 2015 about the same Ohio campaign, “Are we really just turning over all of the benefits of legalization to the privileged white class?”

The industry is all in on passage of the STATES Act, especially with the GOP maintaining control of the Senate in the midterm elections. The bill is the explicit priority of the Cannabis Trade Federation, a new cannabis industry group that includes the same cohort behind New Federalism Fund (NFF).

Neal Levine, the CEO of the Federation, told Cannabis Wire that criminal justice and other priorities are “tremendously important” to the group. But criminal justice could come later. “If some of the other proposals that potentially go further actually had a chance to start moving,” he said, “we would lend our resources to getting behind any proposal that could actually pass into law.”

Levine sees the STATES Act as something that is within reach and necessary. From the industry perspective, the three most concerning issues are the inability of the business to deduct expenses, the “lack of access to banking,” and “the threat that the DOJ can come and seize all your assets and kick in your door at any time,” he said.

“The STATES Act,” he continued, “addresses all three of those issues. And the STATES Act is a bipartisan bill that seems to have support in both houses, and the president said he’d sign it into law. So, if we’re able to fix those issues in the next Congress by actually passing legislation into law, we’re obviously going to pursue that with everything that we have.”

Kevin Sabet, the founder of the leading anti-cannabis organization, Smart Approaches to Marijuana, told Cannabis Wire that he believes the pioneering advocacy groups such as MPP, DPA, and NORML, are being pushed aside. He points out that cannabis companies are hiring some of the biggest lobbying firms in the country, such as Brownstein Hyatt Farber Schreck, to advance their cause. “What I find fascinating is that MPP might have brought these issues to the light,” said Sabet, “but they’re not leaving the dance with who they came with.”

Keith Stroup, the founder of NORML, told Cannabis Wire that while some of NORML’s donors have expressed concerns about new industry interests in the cannabis movement, the focus on business issues is, at least in part, a matter of practicality. “A lot of members of Congress who aren’t yet necessarily willing to embrace full legalization nonetheless recognize that if we’re going to allow individual states to legalize, then we do need to allow them to operate as other legal businesses operate,” said Stroup.

***

What about the future for federal legalization? In many ways, the discussion could be considered premature because Congress fundamentally has done little on the issue (even the STATES Act only has ten cosponsors in the Senate and just twenty-nine in the House). Though, with Rep. Pete Sessions ousted from his role as chair of House Rules Committee where he blocked cannabis-related legislation, and Rep. James McGovern expected to be the Democrats’ replacement, that will likely change.

In fact, the cannabis issue is, at this point, up for grabs.

Democratic and Republican party platforms, both updated in 2016, show that, while the Democratic platform goes much further, neither party has embraced what is now a mainstream issue with majority American support.

The GOP platform takes no position on legal cannabis, noting only, for example, that “the progress made over the last three decades against drug abuse is eroding,” and pointing to the rise in heroin deaths. “In many jurisdictions, marijuana is virtually legalized despite its illegality under federal law,” the platform states. “All this highlights the continuing conflicts and contradictions in public attitudes and public policy toward illegal substances.”

The Democratic Party’s official platform lands somewhere between the priorities of STATES and, for example, the Marijuana Justice Act, introduced by New Jersey Senator Cory Booker. The platform says, “We believe that the states should be laboratories of democracy on the issue of marijuana,” but it also emphasizes the importance of criminal justice, saying, “we recognize our current marijuana laws have had an unacceptable disparate impact in terms of arrest rates for African Americans that far outstrip arrest rates for whites, despite similar usage rates.”

The midterms provide a good example of the Democrats’ reluctance to take the steering wheel on cannabis issues: While a rising number of candidates running for re-election said they are supportive of either medical or adult-use cannabis, it was not often an issue listed on campaign websites or used to rally supporters.

Celinda Lake, a Democratic pollster and strategist, believes her party’s candidates are “way way too intimidated about using the issue,” she told Cannabis Wire. “So we’re not going to see the maximum political impact that we could because candidates don’t realize how wildly popular it is, and frankly underutilize the issue. They’re pulling their punches and they shouldn’t be.”

As Lake sees it, the opportunity for Democrats to hit harder on cannabis reform is clear: “It has had such an energizing effect on two constituencies who really need to get out—millennials and African-American younger men.”

With the somewhat wishy-washy politics of both parties in mind, former Republican House Speaker John Boehner could serve as a harbinger of cannabis’ future. Boehner’s embrace of his role as the industry’s shiny new megaphone has generated intrigue and headlines.

Boehner recently spoke in a promotional video for something called the National Institute for Cannabis Investors, touting membership to the Institute as a way for regular people to profit off the “green gold rush” before cannabis goes fully mainstream. The group, co-founder Mike Ward said in the video, had spent millions pulling together the best research, and Boehner reminded aspiring cannabis investors of his Capitol Hill connections.

The former Speaker told viewers to get involved before Congress and regulators act, and everybody else wakes up to the opportunity. “There’s hundreds of billions of dollars sitting on the sidelines,” he said. “The boat hasn’t left the dock yet.”

He went further, arguing that Big Pharma and Big Tobacco wouldn’t stay out of the cannabis game forever. He promised, using vague language, that Congress would end prohibition. He didn’t say how or which bill would do the trick, and it didn’t seem to matter. The fact that Wall Street and its billions are knocking at the cannabis door seem to be reason enough, in his view, for Congress to act sooner rather than later.

If Big Pharma and Big Tobacco decide to double down, what will the eventual outcome be? Will the cannabis industry, like Big Tobacco, for example, prioritize profits over public health? At that point, will it be too late to remember why the legalization fight began in the first place? Will those who have suffered the consequences of prohibition silently watch as Wall Street traders reap the riches?

Boehner’s free-wheeling use of the phrase “Big Tobacco” was one of the most jarring moments of his infomercial. He meant the phrase to signal opportunity, never mind the industry’s sordid history of deceit. In fact, the comparison to “Big Tobacco” is a pull from the opposition’s playbook: The largest anti-cannabis group in the country, Smart Approaches to Marijuana (SAM), frequently draws the comparison to make its case. “Remember Big Tobacco?,” reads SAM’s homepage. “They’re back.”

Alcohol prohibition is the parallel preferred by most cannabis advocates: In the cases of both alcohol and cannabis, prohibition wasn’t an effective deterrent to consumption, and led to illicit markets and crime; and in both cases, taxpayer dollars went toward combating that crime that could’ve been spent mitigating the public health implications of legal use.

As with any significant national legislation, to see a cannabis bill through Congress, compromise—between players and priorities, between business and justice and politics—will be necessary. Senator Ron Wyden, Democrat of Oregon and a longtime cannabis proponent, acknowledged as much, telling Cannabis Wire that eventually, “Congress will have no choice but to act. It should, however, act now and ensure equal justice for those communities disproportionately hurt” by the status quo. “To get this done, we will need bipartisan support.”

And Wyden added this about the serious harms of ongoing prohibition: “No Republican claiming to support small government—or states’ rights—should be allowed off the hook for supporting the massive government infrastructure surrounding these failed policies.”
 
Last edited:

Marijuana backers plot ambitious campaign


Advocates of legalizing medical and recreational marijuana are planning a wave of new ballot measures in coming years few years, buoyed by wins scored this year's midterm elections in swing and conservative states.

Supporters say they are likely to field measures in states like Ohio and Arizona in 2020, and potentially in Florida and North Dakota. They say plans are underway for initiatives to legalize medical marijuana in Mississippi, Nebraska and South Dakota.

“2020 provides an opportunity to run medical marijuana and legalization campaigns across the country. Typically, presidential elections offer better turnout and a more supportive electorate,” said Matt Schweich, deputy director of the Marijuana Policy Project. “I’d be surprised if there weren’t a large number of initiatives being run — statutory, constitutional, legalization, medical marijuana. It’s going to be a big opportunity for our movement to build momentum.”

Voters in Michigan this year approved Proposal 1, which would set up a regulatory framework for recreational marijuana sales and use. Michigan is the ninth state to allow recreational use, and the only state outside the West and the Northeast where recreational use will be legal.

In Missouri and Utah, voters last Tuesday approved new measures allowing medical marijuana. Oklahoma voters approved their own medical marijuana measure earlier this year. Thirty-three states allow medical marijuana use.

“We won our first state outside of the coasts, and I think there’s a strong feeling that we’re sort of on the downhill of the tipping point,” said one strategist who has worked on legalization measures, who asked for anonymity to describe future plans.

Voters in North Dakota rejected a ballot measure that would have allowed recreational marijuana use. North Dakota became the third state in recent years, after Arizona and Ohio, to reject recreational use.

The strategist said legalization backers have settled on a reliable formula that has generated success at the ballot box. The template includes language allowing adults to grow a small number of marijuana plants in their own home, banning advertising aimed at children and controlling potency of products like edibles that make it to market.

The measures in North Dakota and Ohio did not closely follow that template; the Ohio measure, which did not earn support from the largest groups that back legalization campaigns, went so far as to parade a marijuana leaf mascot — named Bud — around campaign events before it went down in a crushing defeat.

Opponents of marijuana legalization said they have turned their focus to another provision typically found in successful ballot measures, one that allows counties and municipalities to ban pot shops even if recreational marijuana is legal statewide.

“In all states with legalization, the majority of towns and cities that have voted have banned pot shops,” said Kevin Sabet, who heads the drug policy group Smart Approaches to Marijuana, which opposes legalization. “We … think we can get a majority of counties to opt out of pot shops in Michigan.”

A Pew Research Center survey conducted in October showed 62 percent favor legalization — including majorities among Millennials, members of Generation X and the Baby Boomer generation.

Drug legalization is one of the few issues where men take a more liberal stand than women. The Pew Research survey showed 68 percent of men, and just 56 percent of women, support legal pot.

The Utah measure that passed this year is especially notable, Schweich said, because the Republican-dominated state legislature is now likely to take up its own medical marijuana measure. That measure will likely be more conservative than the ballot proposition voters approved, but it will still mark the first time a conservative legislature has approved marijuana use.

“You’re going to see a very conservative state adopt, via its legislature, a medical marijuana law,” he said. “We’ve really showed that any state, no matter how socially conservative it might be, can have medical marijuana.”

The legislative action in Utah is a prelude of what marijuana legalization backers hope becomes the next front in their fight. Not every state allows citizens to change laws via ballot measure; in some states, any change will be up to the legislature.

Two Democratic governors have indicated they would support legalization if the legislature forwards a bill to their desks. New Jersey Gov. Phil Murphy (D) ran into opposition from some Democratic legislators during his first session in office but Illinois Gov.-elect J.B. Pritzker (D) has said he supports legalization.

“We’re going to run out of ballot initiative states. The wins on the ballot initiative front really increase our momentum with legislative work,” Schweich said.

States where medical marijuana is already legal, but where recreational use is still prohibited, are likely to be targets of those legislative pushes. Twenty states allow medical, but not recreational, use.

“The template is, get medical passed first, and then pass recreational,” the pro-pot strategist said.
 
I'm even seeing sales with $200 oz in MD!! Not top shelf, I suspect its stock that must move or be disposed of, but who cares...especially if buying to make edibles.


Marijuana is getting cheaper: Problem for some states?

Marijuana prices are collapsing in Colorado and in other legalization states (e.g., Oregon, where the price can go as low as $100 per pound) because a legal business is dramatically cheaper to operate than an illegal one. Because states generally set their marijuana tax rates as a percentage of price, their revenue per sale sinks in direct proportion to the fall in marijuana prices. Ironically, in a bid for more tax revenue per marijuana sale, Colorado increased its marijuana tax rate from 10 percent to 15 percent last year, only to see the anticipated added tax revenue wiped out by falling prices in a year's time.

States may have failed to anticipate this problem because of misleading predictions about the effects of legalization. Pro-legalization economist Jeffrey Miron projected in 2010 that marijuana prices would only fall 50 percent when prohibition was repealed, leaving the drug at a price that would yield high tax revenue. That was clearly a rosy scenario.

A starker prediction made by drug policy analyst Jonathan Caulkins looks more prescient every day: He forecast that legalized marijuana will eventually fall in price to the level of other easily grown, legal plants like wheat and barley, such that a joint might sell for a nickel or even become a complimentary item akin to beer nuts at the bar. If that comes to pass, taxes based on a percentage of price might not even cover the costs of the government's regulatory system for legal marijuana, meaning that rather than helping states' bottom line the industry would be an outright drain on the public purse.

The simplest way for states to retain some revenue from marijuana sales is to tax the drug by weight, as California has always done and Maine has started to do. The main risk of this approach is that producers will sharply increase product potency to create more "bang per ounce." However, this shortcoming of weight based taxes can be surmounted by capping the allowed potency of marijuana products, a policy for which there is already a good case to be made on public health grounds.
 
Oh for Pete's sake...... god forbid we would get quality cannabis for a reasonable price. :shakehead:
hehehe....now, something I'm kind of noticing here in our somewhat recently med legal state is that in a couple of instances I have gotten some very high THC % strains but guess what....they weren't my favorite.

Its almost like by pushing the genetics so hard to get the THC up, they sacrifices other compounds...or the other compounds are not in the same proportion to the high THC as otherwise may be...and the effects just weren't really there.

I have had some lower THC flower....still 18-22% and the like....that I enjoyed much more because the effects were more well rounded.

Don't get me wrong...32% THC still catches my eye and I don't think anybody knows yet how to read a terpene profile and predict the effects, but certainly THC isn't all of it (as most of us know from first hand experience) but a high THC % on the test label sells. Just does.
 
Well, he should talk to his cousin Patrick who funds and promotes Kevin Sabat and his ridiculous SAM organization.

Joe Kennedy III makes case for federally legalizing marijuana


As legal sales of recreational cannabis began in his home state of Massachusetts, Democratic Rep. Joe Kennedy III has called on the federal government to legalize marijuana. Kennedy made his case for an end to national cannabis prohibition in an op-ed published on Tuesday in the online health and life sciences magazine Stat.

Kennedy wrote in the editorial that Washington has failed in its duty to govern. “Our federal government has ceded its responsibility — and authority — to thoughtfully regulate marijuana,” Kennedy said.

He noted that three more states passed cannabis legalization measures in this month’s midterm elections and that he believes it is time for the federal government to do the same.

“Given the rapid pace of state-level legalization and liberalization, I believe we must implement strong, clear, and fair federal guidelines,” Kennedy said. “To do that requires us to remove marijuana from the Controlled Substances Act (CSA) and legalize it at the federal level.”

New Stance for Kennedy
Kennedy acknowledged that until now he has opposed the legalization of recreational marijuana. “I’ve remained skeptical,” he said, and then went on to explain.

“My reluctance to embrace legalization stems primarily from one place: my ongoing work with the mental health and addiction communities,” said Kennedy. “I’ve seen the devastating effects of drugs that are used and abused. I’ve met family after family torn apart by addiction. And I’ve heard — repeatedly — from mental health advocates on the frontlines who have grave concerns about what access to marijuana might do for those prone to abuse. They worry about research showing marijuana can be addictive, particularly for adolescents.”

But Kennedy agreed also that there are strong arguments for legalizing cannabis.

“At the same time, I’ve heard from others who see marijuana quite differently. The parent whose epileptic child needs marijuana to calm her seizures. The veteran whose trauma it eases. The black teen arrested for smoking a joint while his white friends did the same with impunity.”

“Over the past year, I’ve worked to rectify these perspectives,” Kennedy continued. “I’ve read, I’ve researched, I’ve had countless conversations with people on both sides. One thing is clear to me: Our federal policy on marijuana is badly broken, benefiting neither the elderly man suffering from cancer whom marijuana may help nor the young woman prone to substance use disorder whom it may harm.”

Kennedy said that the prohibition of cannabis has collateral effects that stifle opportunity.

“Banks fear a crackdown on transactions with marijuana suppliers and dispensaries because they are still illegal under federal law, leaving the state-law-abiding businesses no choice but to operate with cash-only transactions,” Kennedy wrote. “Career placement agencies in Springfield that benefit from federal dollars can’t point job seekers down the block to the marijuana dispensary that’s hiring. Affordable housing developers in Foxboro can’t lease to marijuana retailers without fear of losing funding.”

‘Risks Remain’
Kennedy added that ending cannabis prohibition has challenges to be overcome.

“Legalization is not a cure-all. Risks remain and regulatory vigilance is required. Criminal justice inequities will persist until adequate state-level reforms are sought nationwide. But legalization would guide states choosing to move forward with strong and clear national standards meant to ensure that all Americans are protected fully and equally,” said Kennedy.

Less than eight months ago, Kennedy was still publicly against legalizing cannabis. In an appearance on Jimmy Kimmel Live! in April, he admitted that there were not many cannabis prohibitionists like him left in the Democratic Party.

“I acknowledge the fact that I’m an outlier on this, but I just think it’s something we want to be careful and deliberate about as we go forward,” Kennedy said.

Kimmel then noted that in many areas of the country, the movement has already begun. “We moved already. It’s been moved,” he said.
 


Can Artisanal Weed Compete With 'Big Marijuana'?


You’ve heard of Big Pharma and Big Tobacco. How about Big Marijuana?

The drug’s growing legalization is raising concerns among small-scale marijuana farmers and retailers that the corporatization of weed may be right around the corner.

For example, earlier this year NASDAQ became the first major U.S. stock exchange to list shares of a marijuana production company. And in August, Corona-maker Constellation Brands shocked Wall Street by making a US$3.8 billion investment in a Canadian marijuana producer, sparking a bull market in marijuana stocks industry-wide. Even Coca-Cola is exploring opportunities to get involved.

Corporate and Wall Street interest in weed is only going to increase now that three more states have legalized recreational or medicinal marijuana use—bringing the total to 33—while Canada recently became the second country to allow recreational use of the drug.

I have studied the marijuana agriculture industry for the past several years, tracing its evolution from black market drug to legal intoxicant. It’s a story I tell in my book, Craft Weed: Family Farming and the Future of the Marijuana Industry.

With all this money pouring in, it’s fair to wonder how legalization will change the marijuana industry itself—and whether it can stay true to its hippie roots.

Small origins

One of the unintended consequences of the federal prohibition on marijuana in the United States is that legal pot-related businesses have remained rather small.

The American marijuana farming scene, for example, has been dominated by small outdoor farmers and modest indoor warehouse growers. The alternative—large, market-share-dominating companies—would attract the attention of federal authorities.

State governments have recognized a public benefit to keeping farms small and local as well. In California, for example, most marijuana farming licenses are granted to farms limited to no more than one acre of marijuana.

The federal prohibition also prevents farmers, distributors and retailers from engaging in interstate commerce, meaning that states that legalize marijuana use must create their own local markets for homegrown small businesses to operate in.

Moneyed interests

But as the legal marijuana industry booms, well-heeled companies and investors are trying to corner the market.

According to one estimate, consumer spending on legal marijuana products in the U.S. reached $8.5 billion in 2017, up 31 percent from the previous year. Spending is projected to reach $23.4 billion by 2022.

For comparison, beer sales are actually declining. Although total sales were a robust $111 billion in 2017, that was down 1 percent from the previous year.

Such rapid growth in the marijuana market may not be surprising, given that two-thirds of the U.S. population can now use marijuana medicinally or recreationally, up from none just over two decades ago, based on my own analysis.

As a result, retail stores are becoming bigger and bolder, with chains competing to establish themselves as the Starbucks of the marijuana industry.

One of these is Seattle-based Diego Pellicer, one of the first marijuana companies to market itself as a premium brand retail chain. For now, the company’s model rests on acquiring real estate and securing deals with marijuana retailers willing to operate their business under the Diego Pellicer name. That way, if the federal prohibition is ever lifted, Diego Pellicer will be in prime position to dominate the retail market.

The immense growth potential is also attracting private equity and other investors, some of whom are partnering with celebrities whose names are linked to pot smoking. In 2016, for example, a private equity firm partnered with the Bob Marley estate to launch the Marley Natural line of marijuana products.

Patents are seen as another way a few giant companies may come to capture the pot industry. Increasingly well-funded laboratories are developing new strains of marijuana at a rapid pace, with varying degrees of strength and hardiness as well as unique psychoactive and flavor profiles.

As the U.S. Patent and Trade Office begins to issue patents, there are reports of companies attempting to gobble them up.

Finally, many in the agricultural sector of the marijuana industry are predicting and bracing for an agribusiness takeover – though this has yet to happen.

How craft weed can thrive

Are marijuana veterans right to be concerned that their industry is moving too rapidly from the black market to the stock market?

Yes and no. My own research suggests that a local, sustainable and artisanal model of marijuana production can co-exist with Big Marijuana—much as craft beer has thrived in recent years alongside the traditional macro breweries.

One reason is that whereas the illicit drug trade forced consumers to buy marijuana of unknown sources from street dealers, the legal market allows consumers to buy a wide variety of marijuana products from legitimate retail businesses. And more and more consumers are turning to edibles and extracts produced by highly specialized manufacturers.

The staggering number of marijuana strains being developed is creating a connoisseur culture that favors small-scale, artisanal farms that can nimbly adapt to shifts in market demand. Because such farms can market themselves as small, sustainable and local, they can better reflect 21st-century food movement ideals.

Besides efforts at the state level to limit the size of farms, another regulatory approach is the use of appellations to encourage an artisanal pot culture. I have argued that the marijuana industry is well-suited to adopt an appellation system, like you find with wine and cheeses.

Just like a Bordeaux wine comes exclusively from that region of France or Parmigiano-Reggiano is named after the areas of Italy where it originates, Humboldt marijuana may become a prestigious and legally protected designation of origin for marijuana products grown or produced in Humboldt County, California.

It is probably inevitable that Big Marijuana will take hold in some form, but that doesn’t mean the market can’t support the small businesses that have enabled marijuana to become a uniquely local and artisanal industry.
 
Well, I didn't think that opening a S Korea thread under Jurisdictions would be fruitful....doubt we will have too many updates if I did...so I'm posting it here. Please move it @momofthegoons , if you think that's best

South Korea becomes first country in East Asia to legalize medical marijuana

South Korea became the first country in East Asia to legalize medical cannabis, marking a significant milestone in the global industry and a potential turning point in how the drug is perceived in traditionally conservative societies.

The country’s National Assembly voted to approve amending the Act on the Management of Narcotic Drugs to pave the way for non-hallucinogenic dosages of medical cannabis prescriptions.

Medical marijuana will still be tightly restricted, but the law’s approval by the central government is seen as a breakthrough in a country many believed would be last – not among the first – to approve any use of cannabis, even if it is just low-THC, or CBD, to start.

To receive medical cannabis, patients would be required to apply to the Korea Orphan Drug Center, a government body established to facilitate patient access to rare medicines in the country.


Approval would be granted on a case-by-case basis.
Patients would also need to receive a prescription from a medical practitioner.

South Korea’s cannabis law overcame a major obstacle in July when it won the support of the Ministry of Food and Drug Safety, which said at the time it would permit Epidiolex, Marinol, Cesamet and Sativex for conditions including epilepsy, symptoms of HIV/AIDS and cancer-related treatments.

On Nov. 23 the ministry said a series of amended laws passed in a National Assembly session will expand the treatment opportunities for patients with rare diseases.

A number of other countries had been vying to join Israel as the first countries in Asia to allow medical cannabis, including Thailand and Malaysia.

“South Korea legalizing medical cannabis, even if it will be tightly controlled with limited product selection, represents a significant breakthrough for the global cannabis industry,” said Vijay Sappani, CEO of Toronto-based Ela Capital, a venture capital firm exploring emerging markets in the cannabis space.

“The importance of Korea being the first country in East Asia to allow medical cannabis at a federal level should not be understated. Now it’s a matter of when other Asian countries follow South Korea, not if.”
 

Sponsored by

VGoodiez 420EDC
Back
Top